Spain· ES:1191388001IP
POLIVY 140 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION
A medicinal product containing polatuzumab vedotina, registered in Spain by Roche Registration Gmbh.
Checked against AEMPS CIMA (Spain) on
Informational only — not a medical device.
The record
At a glance
AEMPS CIMA (Spain)- Active substance
- polatuzumab vedotina
- Manufacturer
- Roche Registration Gmbh
- Country
- Spain (ES)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- AEMPS CIMA (Spain)
- Last checked
- August 17, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Polatuzumab vedotina in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandPolivyRoche Registration GmbH
- NorwayPolivyOrifarm AS
- CzechiaPOLIVYRoche Registration GmbH, Grenzach-Wyhlen
- United KingdomPolivy 140mg powder for concentrate for solution for infusion vialsRoche Products Ltd
- IrelandPolivy 140 mg powder for concentrate for solution for infusionRoche Registration GmbH
- IcelandPolivyRoche Registration GmbH*
- PolandPolivyRoche Registration GmbH
- BelgiumPolivy 140 mgRoche Registration
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Polivy
- Liechtenstein · Polivy
- Norway · Polivy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/77f31ed6-0019-4191-97a2-9413ef180f3b GET /v1/drugs/77f31ed6-0019-4191-97a2-9413ef180f3b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cpresc": "Uso Hospitalario",
"estado": "{\"aut\":1786534756000}",
"nregistro": "1191388001IP",
"substance": "polatuzumab vedotina"
}See everything about polatuzumab vedotina.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.